This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

DDI regulatory guide

A new European Medicines Agency (EMA) guideline on the investigation of drug interactions (DDI) has recently been adopted and came into effect in January 2013. A new draft US FDA guidance on drug interactions studies (DDI) was released for comment in February 2012.

By popular request from our clients, Cyprotex have assembled an easy-to-follow guide which summarizes the key information from both of these guidance documents. The guide provides a side-by-side comparison of the recommendations from the US and European regulatory authorities which is useful when planning study design. It focuses predominantly on in vitro assessment of DDI.

Please fill in the form below to receive your printed copy of our DDI guide.

Request your printed copy

By clicking on 'Send' I agree that my data is being transferred and used by Cyprotex. For further details please see our privacy policy.

Make enquiry
Other Guides

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close